New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
09:24 EDTTGTXTG Therapeutics poised to advance next week, says Roth Capital
Roth Capital expects TG Therapeutics' A. Phase II combination data from the TG-1101 / Imbruvica study in B-cell malignancies. expected to be presented this weekend, to be strong. The firm expects the stock to rise at the beginning of next week, and it reiterates a Buy rating on the shares. The firm continues to identify the stock as a Focus Pick.
News For TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 10, 2014
10:33 EDTTGTXTG Therapeutics price target raised to $33 from $25 at Roth Capital
December 9, 2014
11:15 EDTTGTXTG Therapeutics announces data of TG-1101 in combination with TGR-1202
Subscribe for More Information
December 8, 2014
13:45 EDTTGTXTG Therapeutics says TG-1101 well tolerated in Phase 2 study
Subscribe for More Information
December 7, 2014
16:16 EDTTGTXTG Therapeutics announces results from Phase l study of TGR-1202
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use